E
IMVT icon

Ergoteles’s Immunovant IMVT Stock Holding History

Ergoteles’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-12,400
Closed -$69K – 1657
2022
Q3 		$69K Sell
12,400
-2,526
-17% -$12.3K ﹤0.01% 1417
2022
Q2 		$58K Buy
+14,926
New +$64.5K ﹤0.01% 1553
2021
Q2 		– Sell
-14,800
Closed -$237K – 1583
2021
Q1 		$237K Buy
+14,800
New +$390K 0.01% 612

Other funds holding IMVT

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Ergoteles's IMVT Position: Q4 2022 in Review

Ergoteles sold out of Immunovant (IMVT) in Q4 2022, closing a stake of 12,400 shares — an estimated $69K sold.

Ergoteles first reported a position in IMVT in Q1 2021 and held it in 3 quarters. The position peaked at $237K in Q1 2021. 133 funds tracked by Wall St. Rank hold IMVT as of Q4 2022.

  • Ergoteles reported no remaining Immunovant position as of Q4 2022 after selling out during the quarter.
  • Ergoteles sold 12,400 Immunovant shares in Q4 2022, an estimated $69K.
  • Ergoteles first reported a position in Immunovant in Q1 2021 and held it in 3 quarters.
  • Ergoteles's Immunovant position peaked at $237K in Q1 2021.
  • 133 funds tracked by Wall St. Rank held Immunovant as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.